Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Target Price from Brokerages

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $7.40.

ATNM has been the subject of a number of research reports. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Actinium Pharmaceuticals by 3.0% in the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after buying an additional 19,843 shares during the period. XTX Topco Ltd bought a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at about $268,000. Wellington Management Group LLP purchased a new stake in Actinium Pharmaceuticals during the 3rd quarter valued at about $112,000. Finally, Los Angeles Capital Management LLC purchased a new position in Actinium Pharmaceuticals in the 3rd quarter worth approximately $322,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $1.44 on Wednesday. The firm has a market cap of $44.92 million, a PE ratio of -1.04 and a beta of 0.07. The stock’s 50 day moving average is $1.46. Actinium Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $10.24.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).